Markets:

Overview

News

Currencies

International

Treasuries

Supernus Pharmaceuticals, Inc. - Common Stock (NQ:SUPN)

50.94 -0.30 (-0.59%)

Streaming Delayed Price Updated: 1:48 PM EST, Jan 8, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Supernus Pharmaceuticals, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 Next >

3 Cash-Heavy Stocks in the Doghouse

May 21, 2025

A cash-heavy balance sheet is often a sign of strength, but not always. Some companies avoid debt because they have weak business models, limited expansion opportunities, or inconsistent cash flow.

Via StockStory

Busy Philipps Empowers Women with ADHD to Go from Feeling Misrepresented to Being ‘Ms. Represented’ in First-of-its-Kind Campaign with Supernus Pharmaceuticals

May 20, 2025

From Supernus Pharmaceuticals, Inc.

Via GlobeNewswire

3 Dawdling Stocks with Mounting Challenges

May 15, 2025

Stability is great, but low-volatility stocks may struggle to deliver market-beating returns over time as they sometimes underperform during bull markets.

Via StockStory

Earnings Scheduled For May 6, 2025 ↗

May 06, 2025

Via Benzinga

3 Stocks Under $50 That Concern Us

May 07, 2025

The $10-50 price range often includes mid-sized businesses with proven track records and plenty of growth runway ahead. They also usually carry less risk than penny stocks, though they’re not immune to...

Via StockStory

Supernus Pharmaceuticals’s (NASDAQ:SUPN) Q1 Sales Beat Estimates But Full-Year Sales Guidance Misses Expectations

May 06, 2025

Specialty pharmaceutical company Supernus Pharmaceuticals (NASDAQ:SUPN) reported revenue ahead of Wall Street’s expectations in Q1 CY2025, with sales up 4.3% year on year to $149.8 million. On the...

Via StockStory

Topics Earnings

Supernus Announces First Quarter 2025 Financial Results

May 06, 2025

From Supernus Pharmaceuticals, Inc.

Via GlobeNewswire

Uncovering Potential: Supernus Pharmaceuticals's Earnings Preview ↗

May 05, 2025

Via Benzinga

Supernus Pharmaceuticals Earnings: What To Look For From SUPN

May 05, 2025

Specialty pharmaceutical company Supernus Pharmaceuticals (NASDAQ:SUPN) will be reporting earnings tomorrow after market close. Here’s what to look for.

Via StockStory

Topics Artificial Intelligence

3 of Wall Street’s Favorite Stocks with Questionable Fundamentals

April 29, 2025

Wall Street is overwhelmingly bullish on the stocks in this article, with price targets suggesting significant upside potential. However, it’s worth remembering that analysts rarely issue sell ratings,...

Via StockStory

3 Healthcare Stocks with Mounting Challenges

April 24, 2025

Personal health and wellness is one of the many secular tailwinds for healthcare companies. Despite the rosy long-term prospects, short-term headwinds such as COVID inventory destocking have harmed the...

Via StockStory

Topics Stocks

Supernus Pharmaceuticals to Announce First Quarter 2025 Financial Results and Host Conference Call and Webcast on May 6, 2025

April 23, 2025

From Supernus Pharmaceuticals, Inc.

Via GlobeNewswire

SUPERNUS PHARMACEUTICALS INC (NASDAQ:SUPN) is a prime example of a stock that offers more than what meets the eye in terms of fundamentals. ↗

April 22, 2025

Uncover the potential of SUPERNUS PHARMACEUTICALS INC, an undervalued stock. NASDAQ:SUPN maintains a strong financial position and offers an appealing valuation.

Via Chartmill

Q4 Earnings Highs And Lows: Eli Lilly (NYSE:LLY) Vs The Rest Of The Branded Pharmaceuticals Stocks

April 10, 2025

Earnings results often indicate what direction a company will take in the months ahead. With Q4 behind us, let’s have a look at Eli Lilly (NYSE:LLY) and its peers.

Via StockStory

Topics Artificial Intelligence Intellectual Property

Q4 Earnings Roundup: Organon (NYSE:OGN) And The Rest Of The Branded Pharmaceuticals Segment

April 08, 2025

Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same sector. Today we are looking at Organon (NYSE:OGN) and the best and worst...

Via StockStory

Topics Artificial Intelligence Intellectual Property

Supernus Pharmaceuticals (SUPN): Buy, Sell, or Hold Post Q4 Earnings?

April 04, 2025

Supernus Pharmaceuticals has been treading water for the past six months, recording a small loss of 1.6% while holding steady at $31.52. However, the stock is beating the S&P 500’s 7% decline during...

Via StockStory

Topics Stocks Supply Chain

A Look Back at Branded Pharmaceuticals Stocks’ Q4 Earnings: Collegium Pharmaceutical (NASDAQ:COLL) Vs The Rest Of The Pack

April 02, 2025

The end of an earnings season can be a great time to discover new stocks and assess how companies are handling the current business environment. Let’s take a look at how Collegium Pharmaceutical...

Via StockStory

Topics Artificial Intelligence Intellectual Property

Unpacking Q4 Earnings: Pfizer (NYSE:PFE) In The Context Of Other Branded Pharmaceuticals Stocks

March 27, 2025

As the Q4 earnings season wraps, let’s dig into this quarter’s best and worst performers in the branded pharmaceuticals industry, including Pfizer (NYSE:PFE) and its peers.

Via StockStory

Topics Artificial Intelligence Intellectual Property

IBD 50's Axsome Therapeutics Dives On Mixed ADHD Results. Why Analysts Aren't Worried. ↗

March 25, 2025

The company is working on a non-stimulant approach to treating ADHD.

Via Investor's Business Daily

Q4 Earnings Highs And Lows: Royalty Pharma (NASDAQ:RPRX) Vs The Rest Of The Branded Pharmaceuticals Stocks

March 21, 2025

The end of an earnings season can be a great time to discover new stocks and assess how companies are handling the current business environment. Let’s take a look at how Royalty Pharma (NASDAQ:RPRX)...

Via StockStory

Topics Artificial Intelligence Intellectual Property

SUPERNUS PHARMACEUTICALS INC (NASDAQ:SUPN) appears to be flying under the radar despite its strong fundamentals. ↗

March 15, 2025

SUPERNUS PHARMACEUTICALS INC may be an undervalued stock option. NASDAQ:SUPN retains a strong financial foundation and an attractive price tag.

Via Chartmill

Q4 Earnings Recap: Supernus Pharmaceuticals (NASDAQ:SUPN) Tops Branded Pharmaceuticals Stocks

March 14, 2025

As the craze of earnings season draws to a close, here’s a look back at some of the most exciting (and some less so) results from Q4. Today, we are looking at branded pharmaceuticals stocks, starting...

Via StockStory

Topics Artificial Intelligence Intellectual Property

3 Small-Cap Stocks Skating on Thin Ice

March 13, 2025

Investors looking for hidden gems should keep an eye on small-cap stocks because they’re frequently overlooked by Wall Street. Many opportunities exist in this part of the market, but it is also a...

Via StockStory

Supernus to Participate in Two Upcoming Investor Conferences

March 04, 2025

From Supernus Pharmaceuticals, Inc.

Via GlobeNewswire

Q4 Earnings Outperformers: Corcept (NASDAQ:CORT) And The Rest Of The Branded Pharmaceuticals Stocks

March 04, 2025

As the Q4 earnings season comes to a close, it’s time to take stock of this quarter’s best and worst performers in the branded pharmaceuticals industry, including Corcept (NASDAQ:CORT) and its peers.

Via StockStory

Topics Artificial Intelligence Intellectual Property

Branded Pharmaceuticals Stocks Q4 In Review: Bristol-Myers Squibb (NYSE:BMY) Vs Peers

March 04, 2025

Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same sector. Today we are looking at Bristol-Myers Squibb (NYSE:BMY) and the best...

Via StockStory

Topics Artificial Intelligence Intellectual Property

Supernus to Participate in the TD Cowen 45th Annual Health Care Conference

February 27, 2025

From Supernus Pharmaceuticals, Inc.

Via GlobeNewswire

Earnings To Watch: Amneal (AMRX) Reports Q4 Results Tomorrow

February 27, 2025

Pharmaceutical company Amneal Pharmaceuticals (NASDAQ:AMRX) will be reporting results tomorrow before market hours. Here’s what investors should know.

Via StockStory

Earnings To Watch: Amphastar Pharmaceuticals (AMPH) Reports Q4 Results Tomorrow

February 26, 2025

Pharmaceutical company Amphastar Pharmaceuticals (NASDAQAMPH) will be reporting earnings tomorrow after market hours. Here’s what to expect.

Via StockStory

Viatris Earnings: What To Look For From VTRS

February 26, 2025

Medication company Viatris (NASDAQ:VTRS) will be reporting results tomorrow before market open. Here’s what to expect.

Via StockStory

< Previous 1 2 3 4 5 6 7 8 9 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.